Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastomaAllison R. Hanaford, Eric H. Raabe, Jesse Alt et al.|Translational Oncology|2019Cited by 74
Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces ApoptosisKhoa Pham, Eric H. Raabe, Micah J. Maxwell et al.|Journal of Neuropathology & Experimental Neurology|2021Cited by 27
Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine PathwaysKhoa Pham, Eric H. Raabe, Jesse Alt et al.|Cancers|2022Cited by 21
OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In <i>Vitro</i> And In <i>Vivo</i> Glucose And Glutamine UsageKhoa Pham, Eric H. Raabe, Brad Poore et al.|Neuro-Oncology Advances|2021Cited by 1
Abstract 5277: Glutamine antagonists synergize with L-asparaginase in MYCN-driven rhabdomyosarcomaMicah J. Maxwell, Eric H. Raabe, Brad Poore et al.|Cancer Research|2019Cited by 0